TLOG (TetraLogic Pharmaceuticals) ROE % Adjusted to Book Value: 0.00% (As of Sep. 2016)


What is TetraLogic Pharmaceuticals ROE % Adjusted to Book Value?

TetraLogic Pharmaceuticals TLOG ROE % Adjusted to Book Value is 0.00% as of Sep. 2016.

TetraLogic Pharmaceuticals's ROE % for the quarter that ended in Sep. 2016 was 0.00%. TetraLogic Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2016 was N/A. TetraLogic Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2016 was N/A.

TetraLogic Pharmaceuticals ROE % Adjusted to Book Value Related Terms

TetraLogic Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals ROE % Adjusted to Book Value Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
ROE % Adjusted to Book Value
0.00 0.00 0.00 -26.61 0.00

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.75 0.00 0.00 0.00 0.00

TLOG vs ARGSQ, GTHR, SOAN: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's ROE % Adjusted to Book Value falls into.


TetraLogic Pharmaceuticals ROE % Adjusted to Book Value Calculation

TetraLogic Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2015 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-362.14% / N/A
=N/A

TetraLogic Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2016 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
TetraLogic Pharmaceuticals (TLOG) has a ROE % Adjusted to Book Value of 0.00% as of Sep. 2016. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TetraLogic Pharmaceuticals and its competitors.
Is TetraLogic Pharmaceuticals' ROE % Adjusted to Book Value too high?
TetraLogic Pharmaceuticals' current ROE % Adjusted to Book Value is 0.00%.
How does TetraLogic Pharmaceuticals' ROE % Adjusted to Book Value compare to ARGSQ and GTHR?
TetraLogic Pharmaceuticals' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TetraLogic Pharmaceuticals and its competitors. TetraLogic Pharmaceuticals's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TetraLogic Pharmaceuticals stock overvalued right now?
TetraLogic Pharmaceuticals (TLOG) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current ROE % Adjusted to Book Value is 0.00% as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.